Companies › Spark Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Ophthalmology, Metabolic and endocrine; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Voretigene Neparvovec Retinoid isomerohydrolase exogenous gene | RPE65 | Phase 3 | Inherited Retinal Dystrophy Due to RPE65 Mutations; Leber Congenital Amaurosis | Oct 2027 |
| SPK-3006 AAV-mediated gene transfer expressing acid alpha-glucosidase (GAA) | GAA | Phase 1 | Pompe Disease | Apr 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01208389 | Voretigene Neparvovec | Phase 1 | Leber Congenital Amaurosis | Ophthalmology | Oct 2027 |
| NCT00999609 | Voretigene Neparvovec | Phase 3 | Inherited Retinal Dystrophy Due to RPE65 Mutations | Ophthalmology | Jan 2030 |
| NCT04093349 | SPK-3006 | Phase 1 | Pompe Disease | Metabolic and endocrine | Apr 2032 |
Innostellar Biotherapeutics Frontera Therapeutics Astellas GeneCradle Amicus Therapeutics Sanofi AskBio
Innostellar Biotherapeutics GenSight Biologics GeneCradle Orchard Therapeutics Shanghai Vitalgen BioPharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.